The February 2026 FDA warning letter addressed marketing language, not safety
Additionally, DonorKids QL found donor characteristics associated with poorer pre-donation HRQoL that included depression (r = -.45 to -.78
Some users find that a microdosing approach produces fewer side effects while still providing meaningful therapeutic benefit
Safe use requires medical supervision, gradual dose titration, and monitoring of metabolic markers such as glucose, digestion response, and weight trends
This is because outside the structure of randomised clinical trials, most people stop using GLP-1s within a year
Daily dosing (micro-dosing) can increase the risk of missed doses, while spacing doses too far apart may lead to hormone fluctuations that affect energy, mood swings, focus, and physical progress